Prospective management of a child with neonatal citrullinemia.
A patient with neonatal citrullinemia caused by severe deficiency of argininosuccinate synthetase was treated prospectively according to the currently accepted protocol. We gradually reduced the doses and then discontinued treatment with sodium benzoate and phenylacetate; blood glutamine levels were maintained in the normal range, but ammonia was mildly elevated. Growth and development progressed normally through 31 months of age. Some patients with citrullinemia can be successfully managed without daily sodium benzoate and phenylacetate therapy.
Melnyk
A R
AR
Department of Pediatrics, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois 60062.
Matalon
R
R
Henry
B W
BW
Zeller
W P
WP
Lange
C
C
D000592:Amino Acid Metabolism, Inborn Errors / Q000188:drug therapy* / Q000503:physiopathology; D000641:Ammonia / Q000097:blood; D001120:Arginine / Q000097:blood / Q000627:therapeutic use; D001124:Argininosuccinate Synthase / Q000172:deficiency; D001565:Benzoates / Q000627:therapeutic use; D019817:Benzoic Acid; D002657:Child Development; D002675:Child, Preschool; D002956:Citrulline / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010648:Phenylacetates / Q000627:therapeutic use
D001565:Benzoates; D010648:Phenylacetates; D002956:Citrulline; D000641:Ammonia; D019817:Benzoic Acid; D001120:Arginine; D001124:Argininosuccinate Synthase; C025136:phenylacetic acid